The Effect of E-Health Management on Gestational Diabetes Control
Randomized Controlled Trail of e-Health Management for Women With Prior Gestational Diabetes Mellitus
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
Background: Women with previous gestational diabetes mellitus are at increased risk for developing type2 diabetes mellitus or metabolic syndrome in their later life. Infants of mothers with GDM are more susceptible to stillbirth and more serious health concerns. With limited time for visits and the predicament of education, applying web-based intervention has become a convenient tool for health management.
Objectives: The approved project aimed to develop an e-heath management platform(eHMP) for women with high risk of gestational diabetes mellitus (GDM) and to evaluate the longitudinal effects between groups of eHMP intervention. The eHMP integrate GDM health care knowledge, self-awareness of health, self-monitoring of health status (i.e., recording weight and measurement data of metabolic syndrome risk factors and monitoring changes in data trends); participation in discussions or browsing forums; healthy lifestyle guidance and counseling; reminder systems, a token system of earning points in exchange for prizes.
Methods: Pregnant women aged 18-45 years with high risk of metabolic syndrome who have a singleton pregnancy, are eligible to participate in this study. Women who agree to participate in the study will be given a participant information sheet and consent form. Participants will be recruited from the Pregnancy diabetes Clinic, at Chang Gung memorial hospital and introduced to the eHMP using the mobile phone in the clinic. Participants will also be given the URL to access to the program and they can learn the modules at home by using their home PCs, mobile phones, or tablets. They were followed up for three times: 28 weeks' gestation, 36-40 weeks' gestation and 6-12 weeks postpartum. SPSS version 20.0 software was used to compile and analyze the research data, including questionnaires and blood test for metabolic index.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Taipei, Taiwan, 10507
- Chang Gung Memorail Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
Pregnant women (pre-pregnancy body mass index ≧ 24) must meet at least one of the following conditions and agree to be interviewed:
- Age over 34 years old;
- Ever had giant infant delivery (weight ≧ 4.5 kg);
- Previous diagnosed with gestational diabetes ;
- Family history of diabetes.
Exclusion Criteria:
- Pre-existing diabetes (types 1 and 2);
- Unable to write and understand Chinese;
- Subject has cognitive impairment;
- Subject has intellectual disability or mental illness;
- Dependent on medical care (eg, anti-depressants, or any psychiatric medication)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: eHMP experimental group
The experimental group received health management support and counseling,including:
|
Pregnant women who agree to take part will be assigned to a group: experimental group and control group.
The experimental group will received health management support and counseling that were conducted by the researchers through the e-health management platform.
Outros nomes:
|
|
Sem intervenção: Control group
only received usual care
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change of Triglyceride Level
Prazo: Change from Baseline at 6-12 weeks after delivery
|
Blood sampling was performed in the fasting state.
Normal triglyceride was <150 mg/dl; ≥150mg/dl was abnormal
|
Change from Baseline at 6-12 weeks after delivery
|
|
Change of Fasting Blood Glucose (FBG) Level
Prazo: Change from Baseline at 6-12 weeks after delivery
|
Blood sampling was performed in the fasting state.
Normal FBG was < 100 mg/dl; ≥100mg/dl was abnormal
|
Change from Baseline at 6-12 weeks after delivery
|
|
Change of high-density lipoprotein cholesterol (HDL) level
Prazo: Change from Baseline at 6-12 weeks after delivery
|
Blood sampling was performed in the fasting state.
Normal HDL was ≥50 mg/dl; <50mg/dl was abnormal
|
Change from Baseline at 6-12 weeks after delivery
|
|
Change of Cholesterol level
Prazo: Change from Baseline at 6-12 weeks after delivery
|
Blood sampling was performed in the fasting state.
Normal Cholesterol was < 200 mg/dl; ≥200mg/dl was abnormal
|
Change from Baseline at 6-12 weeks after delivery
|
|
Change of systolic blood pressure
Prazo: Change from Baseline at 6-12 weeks after delivery
|
Normal systolic blood pressure was <130mmHg; ≥130mmHg was abnormal.
Blood pressure was measured at the right arm twice after a 10-min rest in the supine position by using a calibrated sphygmomanometer and averaged.
|
Change from Baseline at 6-12 weeks after delivery
|
|
Change of diastolic blood pressure
Prazo: Change from Baseline at 6-12 weeks after delivery
|
Normal diastolic blood pressure was <85mmHg; ≥85mmHg was abnormal.
Blood pressure was measured at the right arm twice after a 10-min rest in the supine position by using a calibrated sphygmomanometer and averaged.
|
Change from Baseline at 6-12 weeks after delivery
|
|
Change of body weight
Prazo: Change from Baseline at 6-12 weeks after delivery
|
Women's weight following as assessed using calibrated digital scales
|
Change from Baseline at 6-12 weeks after delivery
|
|
Newborn baby weight
Prazo: at birth
|
Newborn baby weight in normal range (>2500g - <4500g) - dichotomous outcome Yes/No assessed using calibrated digital scales.
|
at birth
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change of Pregnancy Physical Activity Assessment
Prazo: Change from Baseline at 6-12 weeks after delivery
|
There are 12 items in this questionnaire, including two dimensions: exercise and inactivity.
Exercise dimension contained four items to assess the type of physical activity, intensity, duration, frequency during pregnancy.
At least 3 days per week, and each time at least 20-30 minutes, counted as regular exercise (dichotomous outcome Yes/No assessed).
Inactivity dimension contained 8 items, dichotomous outcome Yes/No assessed (score 0-8), higher values represent an inactivity lifestyle.
|
Change from Baseline at 6-12 weeks after delivery
|
|
Change of Dietary Behavioral Characteristics Scale
Prazo: Change from Baseline at 6-12 weeks after delivery
|
The instrument is 17-item Likert-type self-report instrument, used a 5-point response format to obtain data regarding the frequency of reported behaviors (never, rarely, sometimes, usually, always).
It including two dimensions and each scale range as: balanced diet (5 items, scale range 5-25) and diet control behavior (12 items, scale range 12-60).
Higher values represent a better maternal dietary patterns during pregnancy.
|
Change from Baseline at 6-12 weeks after delivery
|
|
Change of Health Promotion Scale
Prazo: Change from Baseline at 6-12 weeks after delivery
|
The instrument is 40-item Likert-type self-report instrument, used a 5-point response format to obtain data regarding the frequency of reported behaviors (never, rarely, sometimes, usually, always).
It including six dimensions and each scale range as: social-support (6 items, scale range 6-30), life-appreciation (8 items, scale range 8-40), health-responsibility (8 items, scale range 8-40), stress-management (9 items, scale range 9-45), nutritional behaviors (5 items, scale range 5-25) and exercise behaviors (4 items, scale range 4-20).
The total score was 40 to 200, higher values represent a better health promotion lifestyle.
|
Change from Baseline at 6-12 weeks after delivery
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Mei-Chen Su, Dr., Chang Gung Memorial Hospital
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 105-4129C
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .